{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:45Z","timestamp":1793400705282,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12265-019-09924-y","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T20:03:30Z","timestamp":1572552210000},"page":"390-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond"],"prefix":"10.1007","volume":"13","author":[{"given":"Mohammed","family":"Alomar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-8975","authenticated-orcid":false,"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"9924_CR1","unstructured":"WHO. World health statistics 2018: monitoring health for the SDGs, sustainable development goals. World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. 2018"},{"key":"9924_CR2","first-page":"2014","volume-title":"Cancer treatment and survivorship facts & figures 2014\u20132015","author":"AC Society","year":"2014","unstructured":"Society, A. C. (2014). Cancer treatment and survivorship facts & figures 2014\u20132015 (p. 2014). Atlanta: American Cancer Society."},{"issue":"6","key":"9924_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000227226","volume":"50","author":"SS Akhtar","year":"1993","unstructured":"Akhtar, S. S., Salim, K. P., & Bano, Z. A. (1993). Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology., 50(6), 441\u2013444.","journal-title":"Oncology."},{"key":"9924_CR4","first-page":"819396","volume":"2014","author":"J Sulpher","year":"2014","unstructured":"Sulpher, J., Dattilo, F., Dent, S., Turek, M., Reaume, M. N., & Johnson, C. (2014). Acute cardiogenic shock induced by infusional 5-fluorouracil. Case Rep Oncol Med, 2014, 819396.","journal-title":"Case Rep Oncol Med"},{"issue":"2","key":"9924_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","volume":"38","author":"J Tamargo","year":"2015","unstructured":"Tamargo, J., Caballero, R., & Delpon, E. (2015). Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf, 38(2), 129\u2013152.","journal-title":"Drug Saf"},{"issue":"8","key":"9924_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.21459","volume":"84","author":"K Fatema","year":"2009","unstructured":"Fatema, K., Gertz, M. A., Barnes, M. E., et al. (2009). Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation. Am J Hematol, 84(8), 499\u2013503.","journal-title":"Am J Hematol"},{"issue":"6","key":"9924_CR7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","volume":"34","author":"V Feliz","year":"2011","unstructured":"Feliz, V., Saiyad, S., Ramarao, S. M., Khan, H., Leonelli, F., & Guglin, M. (2011). Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol, 34(6), 356\u2013359.","journal-title":"Clin Cardiol"},{"issue":"7","key":"9924_CR8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.bmt.1704623","volume":"34","author":"JD Hidalgo","year":"2004","unstructured":"Hidalgo, J. D., Krone, R., Rich, M. W., et al. (2004). Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant, 34(7), 615\u2013619.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"9924_CR9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","volume":"51","author":"E Muchtar","year":"2016","unstructured":"Muchtar, E., Dingli, D., Kumar, S., et al. (2016). Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant, 51(11), 1449\u20131455.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"9924_CR10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/bmt.2009.97","volume":"45","author":"E Peres","year":"2010","unstructured":"Peres, E., Levine, J. E., Khaled, Y. A., et al. (2010). Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant, 45(1), 149\u2013152.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"9924_CR11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","volume":"19","author":"A Singla","year":"2013","unstructured":"Singla, A., Hogan, W. J., Ansell, S. M., et al. (2013). Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant, 19(8), 1233\u20131237.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"9924_CR12","doi-asserted-by":"publisher","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","volume":"10","author":"V Buza","year":"2017","unstructured":"Buza, V., Rajagopalan, B., & Curtis, A. B. (2017). Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol, 10(8), e005443. \nhttps:\/\/doi.org\/10.1161\/CIRCEP.117.005443\n\n.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"9924_CR13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4103\/0971-5851.125262","volume":"34","author":"W Raja","year":"2013","unstructured":"Raja, W., Mir, M. H., Dar, I., Banday, M. A., & Ahmad, I. (2013). Cisplatin induced paroxysmal supraventricular tachycardia. Indian J Med Paediatr Oncol, 34(4), 330\u2013332.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"9924_CR14","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3389\/fphar.2018.01058","volume":"9","author":"X Yang","year":"2018","unstructured":"Yang, X., Li, X., Yuan, M., et al. (2018). Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol, 9, 1058.","journal-title":"Front Pharmacol"},{"issue":"2","key":"9924_CR15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jtcvs.2008.07.055","volume":"137","author":"L Zellos","year":"2009","unstructured":"Zellos, L., Richards, W. G., Capalbo, L., et al. (2009). A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 137(2), 453\u2013458.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"42","key":"9924_CR16","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/sj.onc.1207936","volume":"23","author":"J Kluza","year":"2004","unstructured":"Kluza, J., Marchetti, P., Gallego, M. A., et al. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene., 23(42), 7018\u20137030.","journal-title":"Oncogene."},{"issue":"25","key":"9924_CR17","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","volume":"61","author":"JD Wessler","year":"2013","unstructured":"Wessler, J. D., Grip, L. T., Mendell, J., & Giugliano, R. P. (2013). The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol, 61(25), 2495\u20132502.","journal-title":"J Am Coll Cardiol"},{"key":"9924_CR18","unstructured":"Zukkoor S, Thohan V. Drug-drug interactions of common cardiac medications and chemotherapeutic agents. 2018; \nhttps:\/\/www.acc.org\/latest-in-cardiology\/articles\/2018\/12\/21\/09\/52\/drug-drug-interactions-of-common-cardiac-medications-and-chemotherapeutic-agents\n\n. Accessed 30 Oct 2019"},{"issue":"11","key":"9924_CR19","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel, D., Martin, T., Nooka, A., et al. (2013). Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica., 98(11), 1753\u20131761.","journal-title":"Haematologica."},{"issue":"12","key":"9924_CR20","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I","volume":"74","author":"RL White Jr","year":"1994","unstructured":"White Jr., R. L., Schwartzentruber, D. J., Guleria, A., et al. (1994). Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer., 74(12), 3212\u20133222.","journal-title":"Cancer."},{"issue":"22","key":"9924_CR21","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2012.04.063","volume":"60","author":"Y Guo","year":"2012","unstructured":"Guo, Y., Lip, G. Y., & Apostolakis, S. (2012). Inflammation in atrial fibrillation. J Am Coll Cardiol, 60(22), 2263\u20132270.","journal-title":"J Am Coll Cardiol"},{"key":"9924_CR22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","volume":"4","author":"L Heinzerling","year":"2016","unstructured":"Heinzerling, L., Ott, P. A., Hodi, F. S., et al. (2016). Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 4, 50.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"9924_CR23","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/1755-5922.12475","volume":"36","author":"M Yuan","year":"2018","unstructured":"Yuan, M., Tse, G., Zhang, Z., et al. (2018). The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis. Cardiovasc Ther, 36(6), e12475.","journal-title":"Cardiovasc Ther"},{"issue":"25","key":"9924_CR24","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen, J. R., Boey, E. J., Ooi, J. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. (2014). Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood., 124(25), 3829\u20133830.","journal-title":"Blood."},{"issue":"9","key":"9924_CR25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","volume":"16","author":"L Jiang","year":"2019","unstructured":"Jiang, L., Li, L., Ruan, Y., et al. (2019). Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm, 16(9), 1374\u20131382.","journal-title":"Heart Rhythm"},{"issue":"3","key":"9924_CR26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cjca.2017.12.001","volume":"34","author":"JM Tuomi","year":"2018","unstructured":"Tuomi, J. M., Xenocostas, A., & Jones, D. L. (2018). Increased susceptibility for atrial and ventricular cardiac arrhythmias in mice treated with a single high dose of ibrutinib. Can J Cardiol, 34(3), 337\u2013341.","journal-title":"Can J Cardiol"},{"issue":"12","key":"9924_CR27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra, S., Sharma, A., Shah, S., et al. (2018). Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol, 4(12), 1491\u20131500.","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"9924_CR28","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00280-011-1753-2","volume":"69","author":"I Petrini","year":"2012","unstructured":"Petrini, I., Lencioni, M., Ricasoli, M., et al. (2012). Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol, 69(3), 773\u2013780.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"9924_CR29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","volume":"63","author":"D Farmakis","year":"2014","unstructured":"Farmakis, D., Parissis, J., & Filippatos, G. (2014). Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol, 63(10), 945\u2013953.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"9924_CR30","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1161\/CIRCULATIONAHA.111.019893","volume":"124","author":"YK Iwasaki","year":"2011","unstructured":"Iwasaki, Y. K., Nishida, K., Kato, T., & Nattel, S. (2011). Atrial fibrillation pathophysiology: implications for management. Circulation., 124(20), 2264\u20132274.","journal-title":"Circulation."},{"key":"9924_CR31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1749-8090-7-4","volume":"7","author":"A Imperatori","year":"2012","unstructured":"Imperatori, A., Mariscalco, G., Riganti, G., Rotolo, N., Conti, V., & Dominioni, L. (2012). Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiothorac Surg, 7, 4.","journal-title":"J Cardiothorac Surg"},{"issue":"7","key":"9924_CR32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hlc.2017.06.729","volume":"27","author":"O Kavurmaci","year":"2018","unstructured":"Kavurmaci, O., Akcam, T. I., Ergonul, A. G., Turhan, K., Cakan, A., & Cagirici, U. (2018). Is the risk of postoperative atrial fibrillation predictable in patients undergoing surgery due to primary lung cancer? Heart Lung Circ, 27(7), 835\u2013841.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"9924_CR33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCEP.107.754564","volume":"1","author":"S Nattel","year":"2008","unstructured":"Nattel, S., Burstein, B., & Dobrev, D. (2008). Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol, 1(1), 62\u201373.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"9924_CR34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrcardio.2015.2","volume":"12","author":"YF Hu","year":"2015","unstructured":"Hu, Y. F., Chen, Y. J., Lin, Y. J., & Chen, S. A. (2015). Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol, 12(4), 230\u2013243.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"9924_CR35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacep.2016.08.009","volume":"3","author":"M Mazur","year":"2017","unstructured":"Mazur, M., Wang, F., Hodge, D. O., et al. (2017). Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy. JACC Clin Electrophysiol, 3(2), 139\u2013150.","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"9924_CR36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","volume":"22","author":"S Longhi","year":"2015","unstructured":"Longhi, S., Quarta, C. C., Milandri, A., et al. (2015). Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid., 22(3), 147\u2013155.","journal-title":"Amyloid."},{"issue":"7","key":"9924_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11864-019-0657-y","volume":"20","author":"S Chandrasekhar","year":"2019","unstructured":"Chandrasekhar, S., & Fradley, M. G. (2019). QT interval prolongation associated with cytotoxic and targeted cancer therapeutics. Curr Treat Options in Oncol, 20(7), 55. \nhttps:\/\/doi.org\/10.1007\/s11864-019-0657-y\n\n.","journal-title":"Curr Treat Options in Oncol"},{"issue":"4","key":"9924_CR38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","volume":"124","author":"MG Fradley","year":"2019","unstructured":"Fradley, M. G., Gliksman, M., Emole, J., et al. (2019). Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy. Am J Cardiol, 124(4), 539\u2013544.","journal-title":"Am J Cardiol"},{"issue":"6","key":"9924_CR39","doi-asserted-by":"crossref","first-page":"288e","DOI":"10.1177\/030089161309900622","volume":"99","author":"C Passalia","year":"2013","unstructured":"Passalia, C., Minetto, P., Arboscello, E., et al. (2013). Cardiovascular adverse events complicating the administration of rituximab: report of two cases. Tumori, 99(6), 288e\u2013292e.","journal-title":"Tumori"},{"issue":"25","key":"9924_CR40","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A., Tedeschi, A., Trotman, J., et al. (2018). Phase 3 trial of ibrutinib plus rituximab in Waldenstrom\u2019s macroglobulinemia. N Engl J Med, 378(25), 2399\u20132410.","journal-title":"N Engl J Med"},{"issue":"16","key":"9924_CR41","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond, E. H., Perez, E. A., Bryant, J., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353(16), 1673\u20131684.","journal-title":"N Engl J Med"},{"issue":"11","key":"9924_CR42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344(11), 783\u2013792.","journal-title":"N Engl J Med"},{"issue":"13","key":"9924_CR43","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","volume":"99","author":"C Ozcelik","year":"2002","unstructured":"Ozcelik, C., Erdmann, B., Pilz, B., et al. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A, 99(13), 8880\u20138885.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9924_CR44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd, J. C., Brown, J. R., O\u2019Brien, S., et al. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med, 371(3), 213\u2013223.","journal-title":"N Engl J Med"},{"issue":"10020","key":"9924_CR45","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling, M., Jurczak, W., Jerkeman, M., et al. (2016). Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet., 387(10020), 770\u2013778.","journal-title":"Lancet."},{"issue":"21","key":"9924_CR46","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos, D., Cutler, C. S., Arora, M., et al. (2017). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood., 130(21), 2243\u20132250.","journal-title":"Blood."},{"issue":"15","key":"9924_CR47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P., Tripsas, C. K., Meid, K., et al. (2015). Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N Engl J Med, 372(15), 1430\u20131440.","journal-title":"N Engl J Med"},{"issue":"17","key":"9924_CR48","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien, S., Furman, R. R., Coutre, S., et al. (2018). Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood., 131(17), 1910\u20131919.","journal-title":"Blood."},{"issue":"10","key":"9924_CR49","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown, J. R., Moslehi, J., O\u2019Brien, S., et al. (2017). Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica., 102(10), 1796\u20131805.","journal-title":"Haematologica."},{"issue":"7","key":"9924_CR50","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","volume":"58","author":"TD Shanafelt","year":"2017","unstructured":"Shanafelt, T. D., Parikh, S. A., Noseworthy, P. A., et al. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma, 58(7), 1630\u20131639.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"9924_CR51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd, J. C., Harrington, B., O\u2019Brien, S., et al. (2016). Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med, 374(4), 323\u2013332.","journal-title":"N Engl J Med"},{"issue":"29","key":"9924_CR52","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A., Smith, A. M., Sirisawad, M., et al. (2010). The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A, 107(29), 13075\u201313080.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"9924_CR53","doi-asserted-by":"crossref","first-page":"e0200220","DOI":"10.1371\/journal.pone.0200220","volume":"13","author":"R Figueroa","year":"2018","unstructured":"Figueroa, R., Alfonso, A., Lopez-Picazo, J., et al. (2018). Insights into venous thromboembolism prevention in hospitalized cancer patients: lessons from a prospective study. PLoS One, 13(8), e0200220.","journal-title":"PLoS One"},{"issue":"3","key":"9924_CR54","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurheartj\/ehs314","volume":"34","author":"M Coppens","year":"2013","unstructured":"Coppens, M., Eikelboom, J. W., Hart, R. G., et al. (2013). The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J, 34(3), 170\u2013176.","journal-title":"Eur Heart J"},{"issue":"12","key":"9924_CR55","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","volume":"120","author":"R Patell","year":"2017","unstructured":"Patell, R., Gutierrez, A., Rybicki, L., & Khorana, A. A. (2017). Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol, 120(12), 2182\u20132186.","journal-title":"Am J Cardiol"},{"issue":"6","key":"9924_CR56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","volume":"25","author":"M D\u2019Souza","year":"2018","unstructured":"D\u2019Souza, M., Carlson, N., Fosbol, E., et al. (2018). CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol, 25(6), 651\u2013658.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"9924_CR57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-019-0797-z","volume":"21","author":"IB Rhea","year":"2019","unstructured":"Rhea, I. B., Lyon, A. R., & Fradley, M. G. (2019). Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies. Curr Oncol Rep, 21(5), 45.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"9924_CR58","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361(12), 1139\u20131151.","journal-title":"N Engl J Med"},{"issue":"11","key":"9924_CR59","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger, C. B., Alexander, J. H., McMurray, J. J., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 365(11), 981\u2013992.","journal-title":"N Engl J Med"},{"issue":"10","key":"9924_CR60","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel, M. R., Mahaffey, K. W., Garg, J., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 365(10), 883\u2013891.","journal-title":"N Engl J Med"},{"issue":"3","key":"9924_CR61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","volume":"2","author":"S Shah","year":"2018","unstructured":"Shah, S., Norby, F. L., Datta, Y. H., et al. (2018). Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv, 2(3), 200\u2013209.","journal-title":"Blood Adv"},{"issue":"4","key":"9924_CR62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","volume":"29","author":"S Kamel","year":"2015","unstructured":"Kamel, S., Horton, L., Ysebaert, L., et al. (2015). Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia., 29(4), 783\u2013787.","journal-title":"Leukemia."},{"issue":"26","key":"9924_CR63","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","volume":"124","author":"M Levade","year":"2014","unstructured":"Levade, M., David, E., Garcia, C., et al. (2014). Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood., 124(26), 3991\u20133995.","journal-title":"Blood."},{"issue":"6","key":"9924_CR64","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L., Rule, S., Martin, P., et al. (2013). Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med, 369(6), 507\u2013516.","journal-title":"N Engl J Med"},{"issue":"9","key":"9924_CR65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.recesp.2019.03.017","volume":"72","author":"T Lopez-Fernandez","year":"2019","unstructured":"Lopez-Fernandez, T., Martin-Garcia, A., Roldan Rabadan, I., et al. (2019). Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol (Engl Ed), 72(9), 749\u2013759.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"13","key":"9924_CR66","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jacc.2015.06.028","volume":"66","author":"FA Masoudi","year":"2015","unstructured":"Masoudi, F. A., Calkins, H., Kavinsky, C. J., et al. (2015). 2015 ACC\/HRS\/SCAI left atrial appendage occlusion device societal overview. J Am Coll Cardiol, 66(13), 1497\u20131513.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9924_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","volume":"64","author":"DR Holmes Jr","year":"2014","unstructured":"Holmes Jr., D. R., Kar, S., Price, M. J., et al. (2014). Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol, 64(1), 1\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9924_CR68","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January, C. T., Wann, L. S., Calkins, H., et al. (2019). 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol, 74(1), 104\u2013132.","journal-title":"J Am Coll Cardiol"},{"key":"9924_CR69","doi-asserted-by":"crossref","unstructured":"Ibrutinib. Aust Prescr. 2015;38(5):178-180.","DOI":"10.18773\/austprescr.2015.066"},{"issue":"2","key":"9924_CR70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","volume":"7","author":"MG Fradley","year":"2015","unstructured":"Fradley, M. G., & Moslehi, J. (2015). QT prolongation and oncology drug development. Card Electrophysiol Clin, 7(2), 341\u2013355.","journal-title":"Card Electrophysiol Clin"},{"key":"9924_CR71","first-page":"8","volume":"14","author":"G Tse","year":"2017","unstructured":"Tse, G., Chan, Y. W., Keung, W., & Yan, B. P. (2017). Electrophysiological mechanisms of long and short QT syndromes. Int J Cardiol Heart Vasc, 14, 8\u201313.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"10","key":"9924_CR72","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden, D. M. (2004). Drug-induced prolongation of the QT interval. N Engl J Med, 350(10), 1013\u20131022.","journal-title":"N Engl J Med"},{"issue":"9","key":"9924_CR73","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","volume":"55","author":"BJ Drew","year":"2010","unstructured":"Drew, B. J., Ackerman, M. J., Funk, M., et al. (2010). Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol, 55(9), 934\u2013947.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"9924_CR74","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.5603\/KP.2016.0156","volume":"74","author":"JL Zamorano","year":"2016","unstructured":"Zamorano, J. L., Lancellotti, P., Munoz, D. R., et al. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Kardiol Pol, 74(11), 1193\u20131233.","journal-title":"Kardiol Pol"},{"issue":"2","key":"9924_CR75","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12012-007-0005-5","volume":"7","author":"B Chen","year":"2007","unstructured":"Chen, B., Peng, X., Pentassuglia, L., Lim, C. C., & Sawyer, D. B. (2007). Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol, 7(2), 114\u2013121.","journal-title":"Cardiovasc Toxicol"},{"issue":"18","key":"9924_CR76","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2174\/138161206777585102","volume":"12","author":"D Thomas","year":"2006","unstructured":"Thomas, D., Karle, C. A., & Kiehn, J. (2006). The cardiac hERG\/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des, 12(18), 2271\u20132283.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"9924_CR77","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0092-8674(01)00243-4","volume":"104","author":"MT Keating","year":"2001","unstructured":"Keating, M. T., & Sanguinetti, M. C. (2001). Molecular and cellular mechanisms of cardiac arrhythmias. Cell., 104(4), 569\u2013580.","journal-title":"Cell."},{"issue":"131","key":"9924_CR78","first-page":"131ra150","volume":"4","author":"Z Lu","year":"2012","unstructured":"Lu, Z., Wu, C. Y., Jiang, Y. P., et al. (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med, 4(131), 131ra150.","journal-title":"Sci Transl Med"},{"issue":"1","key":"9924_CR79","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/mol.66.1.33","volume":"66","author":"E Ficker","year":"2004","unstructured":"Ficker, E., Kuryshev, Y. A., Dennis, A. T., et al. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol, 66(1), 33\u201344.","journal-title":"Mol Pharmacol"},{"issue":"19","key":"9924_CR80","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","volume":"21","author":"JT Barbey","year":"2003","unstructured":"Barbey, J. T., Pezzullo, J. C., & Soignet, S. L. (2003). Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol, 21(19), 3609\u20133615.","journal-title":"J Clin Oncol"},{"issue":"33","key":"9924_CR81","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz, G. J., Ritchie, E. K., Carlin, R. F., et al. (2014). Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. J Clin Oncol, 32(33), 3723\u20133728.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9924_CR82","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1289\/ehp.9686","volume":"115","author":"JL Mumford","year":"2007","unstructured":"Mumford, J. L., Wu, K., Xia, Y., et al. (2007). Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environ Health Perspect, 115(5), 690\u2013694.","journal-title":"Environ Health Perspect"},{"issue":"1","key":"9924_CR83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1182\/blood-2006-01-0054","volume":"108","author":"CW Siu","year":"2006","unstructured":"Siu, C. W., Au, W. Y., Yung, C., et al. (2006). Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood., 108(1), 103\u2013106.","journal-title":"Blood."},{"issue":"3","key":"9924_CR84","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cardiores.2004.01.029","volume":"62","author":"H Sun","year":"2004","unstructured":"Sun, H., Oudit, G. Y., Ramirez, R. J., Costantini, D., & Backx, P. H. (2004). The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of Ik,slow currents. Cardiovasc Res, 62(3), 509\u2013520.","journal-title":"Cardiovasc Res"},{"key":"9924_CR85","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0079-6468(08)70005-5","volume":"29","author":"TK Morgan Jr","year":"1992","unstructured":"Morgan Jr., T. K., & Sullivan, M. E. (1992). An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog Med Chem, 29, 65\u2013108.","journal-title":"Prog Med Chem"},{"issue":"12","key":"9924_CR86","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","volume":"6","author":"A Porta-Sanchez","year":"2017","unstructured":"Porta-Sanchez, A., Gilbert, C., Spears, D., et al. (2017). Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc, 6(12), e007724.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"9924_CR87","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/JTO.0b013e3181e3a2d1","volume":"5","author":"FH Blackhall","year":"2010","unstructured":"Blackhall, F. H., O\u2019Brien, M., Schmid, P., et al. (2010). A phase I study of Vandetanib in combination with vinorelbine\/cisplatin or gemcitabine\/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol, 5(8), 1285\u20131288.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"9924_CR88","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00228-015-1831-1","volume":"71","author":"Y Liu","year":"2015","unstructured":"Liu, Y., Liu, Y., Fan, Z. W., Li, J., & Xu, G. G. (2015). Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol, 71(5), 541\u2013547.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"9924_CR89","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","volume":"1","author":"M Malumbres","year":"2001","unstructured":"Malumbres, M., & Barbacid, M. (2001). To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer, 1(3), 222\u2013231.","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"9924_CR90","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J., Neven, P., Chia, S., et al. (2018). Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 36(24), 2465\u20132472.","journal-title":"J Clin Oncol"},{"issue":"7","key":"9924_CR91","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1158\/1078-0432.CCR-12-2926","volume":"19","author":"B Holkova","year":"2013","unstructured":"Holkova, B., Supko, J. G., Ames, M. M., et al. (2013). A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res, 19(7), 1873\u20131883.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"9924_CR92","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, O. A., Horwitz, S., Masszi, T., et al. (2015). Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study. J Clin Oncol, 33(23), 2492\u20132499.","journal-title":"J Clin Oncol"},{"issue":"23","key":"9924_CR93","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","volume":"22","author":"JR Infante","year":"2016","unstructured":"Infante, J. R., Cassier, P. A., Gerecitano, J. F., et al. (2016). A phase I study of the cyclin-dependent kinase 4\/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res, 22(23), 5696\u20135705.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9924_CR94","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000421-199910000-00009","volume":"22","author":"C Kuropkat","year":"1999","unstructured":"Kuropkat, C., Griem, K., Clark, J., Rodriguez, E. R., Hutchinson, J., & Taylor, S. G. (1999). Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol, 22(5), 466\u2013470.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"9924_CR95","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/europace\/eup300","volume":"11","author":"M Guglin","year":"2009","unstructured":"Guglin, M., Aljayeh, M., Saiyad, S., Ali, R., & Curtis, A. B. (2009). Introducing a new entity: chemotherapy-induced arrhythmia. Europace., 11(12), 1579\u20131586.","journal-title":"Europace."},{"issue":"6","key":"9924_CR96","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF02766801","volume":"12","author":"B Sarubbi","year":"1997","unstructured":"Sarubbi, B., Orditura, M., Ducceschi, V., et al. (1997). Ventricular repolarization time indexes following anthracycline treatment. Heart Vessel, 12(6), 262\u2013266.","journal-title":"Heart Vessel"},{"issue":"5","key":"9924_CR97","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1161\/01.RES.53.5.655","volume":"53","author":"O Binah","year":"1983","unstructured":"Binah, O., Cohen, I. S., & Rosen, M. R. (1983). The effects of adriamycin on normal and ouabain-toxic canine Purkinje and ventricular muscle fibers. Circ Res, 53(5), 655\u2013662.","journal-title":"Circ Res"},{"issue":"39","key":"9924_CR98","doi-asserted-by":"crossref","first-page":"25738","DOI":"10.18632\/oncotarget.25008","volume":"9","author":"J Duan","year":"2018","unstructured":"Duan, J., Tao, J., Zhai, M., et al. (2018). Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget., 9(39), 25738\u201325749.","journal-title":"Oncotarget."},{"issue":"1","key":"9924_CR99","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas, C., Kallistratos, M. S., Kopterides, P., et al. (2008). Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol, 134(1), 75\u201382.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"9924_CR100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","volume":"15","author":"T Sudhoff","year":"2004","unstructured":"Sudhoff, T., Enderle, M. D., Pahlke, M., et al. (2004). 5-Fluorouracil induces arterial vasocontractions. Ann Oncol, 15(4), 661\u2013664.","journal-title":"Ann Oncol"},{"issue":"2","key":"9924_CR101","doi-asserted-by":"crossref","first-page":"e000701","DOI":"10.1136\/openhrt-2017-000701","volume":"4","author":"MG Fradley","year":"2017","unstructured":"Fradley, M. G., Viganego, F., Kip, K., et al. (2017). Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart, 4(2), e000701.","journal-title":"Open Heart"},{"issue":"7","key":"9924_CR102","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/02841869109091832","volume":"30","author":"NK Raabe","year":"1991","unstructured":"Raabe, N. K., & Storstein, L. (1991). Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration. An evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring. Acta Oncol, 30(7), 843\u2013846.","journal-title":"Acta Oncol"},{"issue":"2","key":"9924_CR103","first-page":"345","volume":"41","author":"RC Aversano","year":"1983","unstructured":"Aversano, R. C., & Boor, P. J. (1983). Acute doxorubicin-induced cardiac arrhythmias during ether anesthesia. Res Commun Chem Pathol Pharmacol, 41(2), 345\u2013348.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"1-3","key":"9924_CR104","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0014-5793(03)00743-9","volume":"548","author":"J Gorelik","year":"2003","unstructured":"Gorelik, J., Vodyanoy, I., Shevchuk, A. I., Diakonov, I. A., Lab, M. J., & Korchev, Y. E. (2003). Esmolol is antiarrhythmic in doxorubicin-induced arrhythmia in cultured cardiomyocytes - determination by novel rapid cardiomyocyte assay. FEBS Lett, 548(1-3), 74\u201378.","journal-title":"FEBS Lett"},{"issue":"5","key":"9924_CR105","first-page":"324","volume":"46","author":"TS Bischiniotis","year":"2005","unstructured":"Bischiniotis, T. S., Lafaras, C. T., Platogiannis, D. N., Moldovan, L., Barbetakis, N. G., & Katseas, G. P. (2005). Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hell J Cardiol, 46(5), 324\u2013329.","journal-title":"Hell J Cardiol"},{"issue":"8","key":"9924_CR106","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra, S., & Neilan, T. G. (2018). Immune checkpoint inhibitor-associated myocarditis. Oncologist., 23(8), 879\u2013886.","journal-title":"Oncologist."},{"issue":"3","key":"9924_CR107","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga, C. L., & Engelman, J. A. (2014). ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell, 25(3), 282\u2013303.","journal-title":"Cancer Cell"},{"issue":"17","key":"9924_CR108","doi-asserted-by":"crossref","first-page":"10261","DOI":"10.1074\/jbc.273.17.10261","volume":"273","author":"YY Zhao","year":"1998","unstructured":"Zhao, Y. Y., Sawyer, D. R., Baliga, R. R., et al. (1998). Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem, 273(17), 10261\u201310269.","journal-title":"J Biol Chem"},{"issue":"4","key":"9924_CR109","first-page":"3141","volume":"17","author":"P Rao","year":"2019","unstructured":"Rao, P., Liu, Z., Duan, H., et al. (2019). Pretreatment with neuregulin-1 improves cardiac electrophysiological properties in a rat model of myocardial infarction. Exp Ther Med, 17(4), 3141\u20133149.","journal-title":"Exp Ther Med"},{"issue":"9","key":"9924_CR110","doi-asserted-by":"publisher","first-page":"e006915","DOI":"10.1161\/JAHA.117.006915","volume":"6","author":"R Florido","year":"2017","unstructured":"Florido, R., Smith, K. L., Cuomo, K. K., & Russell, S. D. (2017). Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies. J Am Heart Assoc, 6(9), e006915. \nhttps:\/\/doi.org\/10.1161\/JAHA.117.006915\n\n.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"9924_CR111","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.622","volume":"5","author":"SH Ou","year":"2016","unstructured":"Ou, S. H., Tang, Y., Polli, A., Wilner, K. D., & Schnell, P. (2016). Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med, 5(4), 617\u2013622.","journal-title":"Cancer Med"},{"key":"9924_CR112","first-page":"1","volume":"3","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z., Huang, T. Q., Nepliouev, I., et al. (2017). Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity. Cardiooncology., 3, 1.","journal-title":"Cardiooncology."},{"issue":"2 Supp 1","key":"9924_CR113","first-page":"57","volume":"21","author":"EA Mostaghel","year":"2014","unstructured":"Mostaghel, E. A., & Lin, D. W. (2014). Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol, 21(2 Supp 1), 57\u201363.","journal-title":"Can J Urol"},{"issue":"2","key":"9924_CR114","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson, L., Dahl, M. L., Dalen, P., & Al-Shurbaji, A. (2002). Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol, 53(2), 111\u2013122.","journal-title":"Br J Clin Pharmacol"},{"key":"9924_CR115","first-page":"117","volume":"15","author":"SG Arbuck","year":"1993","unstructured":"Arbuck, S. G., Strauss, H., Rowinsky, E., et al. (1993). A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr, 15, 117\u2013130.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"6","key":"9924_CR116","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11912-018-0691-0","volume":"20","author":"MA Armanious","year":"2018","unstructured":"Armanious, M. A., Mishra, S., & Fradley, M. G. (2018). Electrophysiologic toxicity of chemoradiation. Curr Oncol Rep, 20(6), 45. \nhttps:\/\/doi.org\/10.1007\/s11912-018-0691-0\n\n.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"9924_CR117","first-page":"430","volume":"62","author":"MA Khan","year":"2012","unstructured":"Khan, M. A., Masood, N., Husain, N., Ahmad, B., Aziz, T., & Naeem, A. (2012). A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc, 62(5), 430\u2013434.","journal-title":"J Pak Med Assoc"},{"issue":"4","key":"9924_CR118","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","volume":"111","author":"WP McGuire","year":"1989","unstructured":"McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., et al. (1989). Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med, 111(4), 273\u2013279.","journal-title":"Ann Intern Med"},{"issue":"Suppl 5","key":"9924_CR119","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","volume":"21","author":"D Bovelli","year":"2010","unstructured":"Bovelli, D., Plataniotis, G., Roila, F., & Group EGW. (2010). Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol, 21(Suppl 5), v277\u2013v282.","journal-title":"Ann Oncol"},{"key":"9924_CR120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O., Sau, S., Alzhrani, R., et al. (2017). PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol, 8, 561.","journal-title":"Front Pharmacol"},{"issue":"16","key":"9924_CR121","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S., Fradley, M. G., Cohen, J. V., et al. (2018). Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol, 71(16), 1755\u20131764.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"9924_CR122","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.2169\/internalmedicine.0255-17","volume":"57","author":"Y Katsume","year":"2018","unstructured":"Katsume, Y., Isawa, T., Toi, Y., et al. (2018). Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med, 57(21), 3157\u20133162.","journal-title":"Intern Med"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-019-09924-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-019-09924-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-019-09924-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T01:07:32Z","timestamp":1604020052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-019-09924-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["9924"],"URL":"https:\/\/doi.org\/10.1007\/s12265-019-09924-y","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"16 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Fradley has served as a consultant\/advisor for Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}